Wěi Li

72.4k total citations · 12 hit papers
1.4k papers, 44.8k citations indexed

About

Wěi Li is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wěi Li has authored 1.4k papers receiving a total of 44.8k indexed citations (citations by other indexed papers that have themselves been cited), including 567 papers in Molecular Biology, 356 papers in Oncology and 202 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wěi Li's work include Lung Cancer Treatments and Mutations (79 papers), HER2/EGFR in Cancer Research (71 papers) and Synthesis and biological activity (65 papers). Wěi Li is often cited by papers focused on Lung Cancer Treatments and Mutations (79 papers), HER2/EGFR in Cancer Research (71 papers) and Synthesis and biological activity (65 papers). Wěi Li collaborates with scholars based in China, United States and Australia. Wěi Li's co-authors include Duane D. Miller, Andrzej Słomiński, Robert C. Tuckey, Chunlei Liu, Tae‐Kang Kim, Jianjun Chen, Bing Wu, Yan Lü, Zorica Janjetović and Jin Wang and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Wěi Li

1.4k papers receiving 44.2k citations

Hit Papers

Olaparib for Metastatic B... 2011 2026 2016 2021 2017 2014 2015 2012 2011 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
    2017 2.2k citations Wěi Li et al. profile →
  2. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    2014 1.6k citations Jifeng Feng, Wěi Li et al. profile →
  3. HIF-1α pathway: role, regulation and intervention for cancer therapy
    2015 1.4k citations Wěi Li et al. profile →
  4. An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
    2012 626 citations Jianjun Chen, Wěi Li et al. profile →
  5. Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition
    2011 503 citations Wěi Li et al. profile →
  6. Suppression of cancer relapse and metastasis by inhibiting cancer stemness
    2015 382 citations Wěi Li et al. profile →
  7. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
    2015 324 citations Wěi Li et al. profile →
  8. Antibody–drug conjugates: Recent advances in payloads
    2023 130 citations Wěi Li, Yuxi Wang et al. profile →
  9. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
    2024 56 citations Wěi Li et al. profile →
  10. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
    2024 53 citations Wěi Li et al. profile →
  11. Biological Effects of CYP11A1-Derived Vitamin D and Lumisterol Metabolites in the Skin
    2024 45 citations Wěi Li et al. profile →
  12. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
    2025 16 citations Wěi Li et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Wěi Li 18.3k 10.0k 6.6k 6.2k 4.7k 1.4k 44.8k
Gautam Sethi 26.2k 1.4× 8.7k 0.9× 9.1k 1.4× 2.6k 0.4× 3.3k 0.7× 615 48.2k
Eleftherios P. Diamandis 17.2k 0.9× 9.7k 1.0× 6.2k 0.9× 5.8k 0.9× 790 0.2× 940 44.5k
Chen Chen 19.5k 1.1× 3.8k 0.4× 5.7k 0.9× 2.3k 0.4× 2.9k 0.6× 2.5k 51.4k
Takashi Takahashi 19.7k 1.1× 11.2k 1.1× 9.0k 1.4× 6.3k 1.0× 963 0.2× 699 37.1k
Takashi Sügimura 24.4k 1.3× 10.7k 1.1× 13.6k 2.0× 2.2k 0.4× 5.6k 1.2× 1.2k 50.0k
Michael B. Sporn 44.7k 2.4× 12.8k 1.3× 8.6k 1.3× 5.4k 0.9× 1.9k 0.4× 512 73.5k
John N. Weinstein 22.9k 1.2× 6.9k 0.7× 7.1k 1.1× 3.0k 0.5× 1.2k 0.3× 322 34.9k
Seppo Ylä‐Herttuala 21.8k 1.2× 9.9k 1.0× 4.6k 0.7× 2.5k 0.4× 1.0k 0.2× 748 44.5k
Antonio Giordano 19.5k 1.1× 13.8k 1.4× 6.3k 1.0× 4.1k 0.7× 754 0.2× 874 36.6k
Peng Huang 18.0k 1.0× 5.8k 0.6× 7.4k 1.1× 2.9k 0.5× 3.2k 0.7× 329 31.3k

Countries citing papers authored by Wěi Li

Since Specialization
Citations

This map shows the geographic impact of Wěi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wěi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wěi Li more than expected).

Fields of papers citing papers by Wěi Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wěi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wěi Li. The network helps show where Wěi Li may publish in the future.

Co-authorship network of co-authors of Wěi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Wěi Li. A scholar is included among the top collaborators of Wěi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wěi Li. Wěi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Wěi, Cong Wang, Jian Ruan, et al.. (2025). Identification of novel non-covalent Mpro inhibitors against SARS-CoV-2 by the computational and experimental approaches. Journal of Molecular Graphics and Modelling. 141. 109151–109151.
2.
Wang, Didi, et al.. (2024). Highly oxygenated clerodane furanoditerpenoids from the leaves and twigs of Croton yunnanensis. Chinese Journal of Natural Medicines. 22(10). 945–954. 4 indexed citations
3.
Qiu, Zhiwen, et al.. (2023). Effects of polymer terminal group inside micelle core on paclitaxel loading promoting and burst release suppressing. Journal of Gastrointestinal Oncology. 14(4). 1659–1668. 3 indexed citations
4.
Shang, Junkui, Dandan Gao, Ruihua Sun, et al.. (2023). Presenilin2 D439A Mutation Induces Dysfunction of Mitochondrial Fusion/Fission Dynamics and Abnormal Regulation of GTPase Activity. Molecular Neurobiology. 61(8). 5047–5070. 9 indexed citations
5.
Ren, Shengxiang, Jia Yu, Ai‐Sheng Xiong, et al.. (2023). P2.14-07 Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial. Journal of Thoracic Oncology. 18(11). S373–S374.
6.
Yang, Zhihui, Xin Cai, Zhongli Ding, et al.. (2023). Identification of a psychiatric risk gene NISCH at 3p21.1 GWAS locus mediating dendritic spine morphogenesis and cognitive function. BMC Medicine. 21(1). 254–254. 2 indexed citations
7.
Zhang, Mengmeng, Qiao Wang, Zhenxia Chen, et al.. (2023). Gelothermal Synthesis of Monodisperse MIL‐88A Nanoparticles with Tunable Sizes and Metal Centers for Potential Bioapplications. Small. 19(34). e2301894–e2301894. 21 indexed citations
8.
Xing, Ligang, Yueyin Pan, Yuankai Shi, et al.. (2020). Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clinical Cancer Research. 26(23). 6168–6175. 28 indexed citations
9.
Zhao, Guannan, Qinghui Wang, Zhongzhi Wu, et al.. (2019). Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor. Molecular Cancer Therapeutics. 18(12). 2233–2245. 33 indexed citations
10.
Arnst, Kinsie E., Yuxi Wang, Dong‐Jin Hwang, et al.. (2017). A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance. Cancer Research. 78(1). 265–277. 100 indexed citations
11.
Miller, Michael L., Nathan Fishkin, Wěi Li, et al.. (2016). A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity. Molecular Cancer Therapeutics. 15(8). 1870–1878. 65 indexed citations
12.
Hikita, Hayato, Takahiro Kodama, Satoshi Tanaka, et al.. (2015). Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis. Cancer Prevention Research. 8(8). 693–701. 20 indexed citations
13.
Sowalsky, Adam G., Zheng Xia, Liguo Wang, et al.. (2014). Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Research. 13(1). 98–106. 84 indexed citations
14.
Yang, Ge, Yang Fu, Margarita Malakhova, et al.. (2014). Caffeic Acid Directly Targets ERK1/2 to Attenuate Solar UV-Induced Skin Carcinogenesis. Cancer Prevention Research. 7(10). 1056–1066. 47 indexed citations
15.
Wang, Jin, Jianjun Chen, Duane D. Miller, & Wěi Li. (2013). Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma. Molecular Cancer Therapeutics. 13(1). 16–26. 26 indexed citations
16.
Zheng, Jian, Jieqiong Deng, Mang Xiao, et al.. (2013). A Sequence Polymorphism in miR-608 Predicts Recurrence after Radiotherapy for Nasopharyngeal Carcinoma. Cancer Research. 73(16). 5151–5162. 49 indexed citations
17.
Ying, Zhe, Yun Li, Jueheng Wu, et al.. (2012). Loss of miR-204 Expression Enhances Glioma Migration and Stem Cell-like Phenotype. Cancer Research. 73(2). 990–999. 129 indexed citations
18.
Zhang, Chunpeng, Liguo Wang, Dayong Wu, et al.. (2011). Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer. Cancer Research. 71(21). 6738–6748. 73 indexed citations
19.
Li, Wěi, Bu-Er Wang, Paul Moran, et al.. (2009). Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis. Cancer Research. 69(21). 8395–8402. 44 indexed citations
20.
Yokoe, Shunichi, Motoko Takahashi, Michio Asahi, et al.. (2007). The Asn418-Linked N -Glycan of ErbB3 Plays a Crucial Role in Preventing Spontaneous Heterodimerization and Tumor Promotion. Cancer Research. 67(5). 1935–1942. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gautam Sethi Breakdown of academic impact, for papers by Eleftherios P. Diamandis Breakdown of academic impact, for papers by Chen Chen Breakdown of academic impact, for papers by Takashi Takahashi Breakdown of academic impact, for papers by Takashi Sügimura Breakdown of academic impact, for papers by Michael B. Sporn Breakdown of academic impact, for papers by John N. Weinstein Breakdown of academic impact, for papers by Seppo Ylä‐Herttuala Breakdown of academic impact, for papers by Antonio Giordano Breakdown of academic impact, for papers by Peng Huang
Rankless by CCL
2026